Shares of Zoetis Inc (NYSE:ZTS) have earned an average recommendation of “Hold” from the seventeen analysts that are currently covering the company. Three investment analysts have rated the stock with a sell rating, four have issued a hold rating, nine have given a buy rating and one has issued a strong buy rating on the company. The average 1 year price target among analysts that have covered the stock in the last year is $56.94.
ZTS has been the topic of several research reports. Off Wall Street reiterated a “strong sell” rating and set a $35.00 price objective on shares of Zoetis in a research note on Thursday, February 16th. Craig Hallum initiated coverage on shares of Zoetis in a research note on Wednesday, March 15th. They set a “buy” rating and a $65.00 price objective on the stock. Zacks Investment Research lowered shares of Zoetis from a “buy” rating to a “hold” rating in a research note on Saturday, January 7th. Guggenheim increased their price objective on shares of Zoetis from $60.00 to $65.00 and gave the stock a “buy” rating in a research note on Thursday, February 16th. Finally, Jefferies Group LLC increased their price objective on shares of Zoetis from $62.00 to $64.00 and gave the stock a “buy” rating in a research note on Friday, January 20th.
ILLEGAL ACTIVITY NOTICE: “Zoetis Inc (ZTS) Receives $56.94 Consensus Target Price from Brokerages” was first reported by Chaffey Breeze and is the property of of Chaffey Breeze. If you are reading this piece of content on another domain, it was stolen and reposted in violation of US & international trademark & copyright laws. The correct version of this piece of content can be viewed at https://www.chaffeybreeze.com/2017/04/20/zoetis-inc-zts-given-average-recommendation-of-hold-by-brokerages-updated-updated.html.
Shares of Zoetis (NYSE:ZTS) traded up 0.82% on Friday, reaching $54.29. The company had a trading volume of 2,233,370 shares. The company has a 50 day moving average of $53.47 and a 200-day moving average of $52.49. Zoetis has a 52 week low of $45.28 and a 52 week high of $56.50. The company has a market capitalization of $26.71 billion, a P/E ratio of 32.90 and a beta of 1.07.
Zoetis (NYSE:ZTS) last released its quarterly earnings data on Thursday, February 16th. The company reported $0.47 earnings per share for the quarter, topping the consensus estimate of $0.45 by $0.02. The firm had revenue of $1.30 billion for the quarter, compared to analyst estimates of $1.28 billion. Zoetis had a net margin of 14.10% and a return on equity of 72.96%. Zoetis’s quarterly revenue was up .2% on a year-over-year basis. During the same quarter in the prior year, the business earned $0.43 earnings per share. Analysts predict that Zoetis will post $2.32 earnings per share for the current fiscal year.
The business also recently disclosed a quarterly dividend, which will be paid on Thursday, June 1st. Stockholders of record on Thursday, April 6th will be issued a $0.105 dividend. This represents a $0.42 annualized dividend and a dividend yield of 0.77%. The ex-dividend date of this dividend is Tuesday, April 4th. Zoetis’s dividend payout ratio (DPR) is presently 30.44%.
Hedge funds and other institutional investors have recently bought and sold shares of the stock. First Manhattan Co. boosted its position in Zoetis by 50.8% in the third quarter. First Manhattan Co. now owns 8,740 shares of the company’s stock valued at $454,000 after buying an additional 2,945 shares during the period. Deltec Asset Management LLC bought a new position in Zoetis during the third quarter valued at about $520,000. DAVENPORT & Co LLC bought a new position in Zoetis during the third quarter valued at about $14,868,000. Eastern Bank acquired a new stake in shares of Zoetis during the third quarter worth $208,000. Finally, National Pension Service boosted its stake in shares of Zoetis by 8.4% in the third quarter. National Pension Service now owns 366,826 shares of the company’s stock worth $19,079,000 after buying an additional 28,279 shares during the last quarter. Institutional investors and hedge funds own 94.54% of the company’s stock.
Zoetis Company Profile
Zoetis Inc is engaged in the discovery, development, manufacture and commercialization of animal health medicines and vaccines, with a focus on both livestock and companion animals. The Company has a business, commercializing products across eight core species: cattle, swine, poultry, sheep and fish (collectively, livestock) and dogs, cats and horses (collectively, companion animals), and within five product categories: anti-infectives, vaccines, parasiticides, medicated feed additives and other pharmaceuticals.
Receive News & Ratings for Zoetis Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis Inc and related companies with MarketBeat.com's FREE daily email newsletter.